Comparison of patients with SLE with thromboembolism
. | Venous thromboembolism . | . | . | Arterial thromboembolism . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | + . | - . | P . | + . | - . | P . | ||||
| No. | 15 | 129 | — | 16 | 128 | — | ||||
| Age at study entry, y | 40 (19-73) | 41 (21-76) | .83 | 48 (28-75) | 41 (19-76) | .038 | ||||
| Age at diagnosis SLE, y | 29 (17-62) | 30 (9-73) | .81 | 37 (15-73) | 30 (9-71) | .25 | ||||
| SLEDAI score | 2 (0-25) | 2 (0-12) | .59 | 2 (0-8) | 2 (0-25) | .35 | ||||
| SLICC/ACR-DI score | 1 (0-3) | 0 (0-5) | .39 | 2 (0-5) | 0 (0-4) | < .001 | ||||
| Lupus anticoagulant | 4 (27) | 7 (5.5) | .017 | 3 (19) | 8 (6.3) | .11 | ||||
| Anticardiolipin antibodies | 3 (20) | 9 (7.0) | .13 | 4 (27) | 8 (7.0) | .03 | ||||
| IgG ≥ 40 GPL | 1 (6.7) | 3 (2.4) | .37 | 2 (13) | 2 (1.6) | .058 | ||||
| IgM ≥ 40 MPL | 2 (13) | 7 (5.7) | .25 | 2 (13) | 7 (5.7) | .25 | ||||
| Antithrombin deficiency | 1 (6.7) | 4 (3.1) | .43 | 1 (6.3) | 4 (3.1) | .45 | ||||
| Protein C deficiency | 0 | 3 (2.3) | 1.00 | 0 | 3 (2.3) | .75 | ||||
| Protein S deficiency | ||||||||||
| Type I | 0 | 4 (3.1) | 1.00 | 0 | 4 (3.2) | .99 | ||||
| Type III* | 5 (71) | 42 (70) | 1.00 | 9 (82) | 38 (68) | .48 | ||||
| Plasminogen deficiency | 0 | 1 (0.8) | 1.00 | 0 | 1 (0.8) | .99 | ||||
| APC resistance | 6 (40) | 43 (35) | .78 | 5 (36) | 44 (35) | .99 | ||||
| Factor V Leiden | 3 (20) | 8 (6.4) | .097 | 0 | 11 (8.8) | .61 | ||||
| Prothrombin G20210A | 2 (13) | 0 | .011 | 0 | 2 (1.6) | .99 | ||||
. | Venous thromboembolism . | . | . | Arterial thromboembolism . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | + . | - . | P . | + . | - . | P . | ||||
| No. | 15 | 129 | — | 16 | 128 | — | ||||
| Age at study entry, y | 40 (19-73) | 41 (21-76) | .83 | 48 (28-75) | 41 (19-76) | .038 | ||||
| Age at diagnosis SLE, y | 29 (17-62) | 30 (9-73) | .81 | 37 (15-73) | 30 (9-71) | .25 | ||||
| SLEDAI score | 2 (0-25) | 2 (0-12) | .59 | 2 (0-8) | 2 (0-25) | .35 | ||||
| SLICC/ACR-DI score | 1 (0-3) | 0 (0-5) | .39 | 2 (0-5) | 0 (0-4) | < .001 | ||||
| Lupus anticoagulant | 4 (27) | 7 (5.5) | .017 | 3 (19) | 8 (6.3) | .11 | ||||
| Anticardiolipin antibodies | 3 (20) | 9 (7.0) | .13 | 4 (27) | 8 (7.0) | .03 | ||||
| IgG ≥ 40 GPL | 1 (6.7) | 3 (2.4) | .37 | 2 (13) | 2 (1.6) | .058 | ||||
| IgM ≥ 40 MPL | 2 (13) | 7 (5.7) | .25 | 2 (13) | 7 (5.7) | .25 | ||||
| Antithrombin deficiency | 1 (6.7) | 4 (3.1) | .43 | 1 (6.3) | 4 (3.1) | .45 | ||||
| Protein C deficiency | 0 | 3 (2.3) | 1.00 | 0 | 3 (2.3) | .75 | ||||
| Protein S deficiency | ||||||||||
| Type I | 0 | 4 (3.1) | 1.00 | 0 | 4 (3.2) | .99 | ||||
| Type III* | 5 (71) | 42 (70) | 1.00 | 9 (82) | 38 (68) | .48 | ||||
| Plasminogen deficiency | 0 | 1 (0.8) | 1.00 | 0 | 1 (0.8) | .99 | ||||
| APC resistance | 6 (40) | 43 (35) | .78 | 5 (36) | 44 (35) | .99 | ||||
| Factor V Leiden | 3 (20) | 8 (6.4) | .097 | 0 | 11 (8.8) | .61 | ||||
| Prothrombin G20210A | 2 (13) | 0 | .011 | 0 | 2 (1.6) | .99 | ||||
Continuous variables denoted as median (range), categorical variables as number (%). — indicates not applicable.
Measured in the first 67 enrolled patients.